SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Ablynx's Partner Shows That a Nanobody Can Elicit Superior Anti-Tumour Efficacy Compared to Conventional Monoclonal Antibody Approaches